Price of anoro ellipta?

The price of Anoro Ellipta can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location. As a prescription medication, it is not typically sold with a fixed retail price, and patient out-of-pocket costs are often determined by individual insurance plans and their formulary coverage for Anoro Ellipta.

What influences the cost of Anoro Ellipta?

The list price of Anoro Ellipta can be several hundred dollars for a one-month supply. However, this is rarely the amount paid by a patient. Insurance companies negotiate prices with manufacturers, and the patient's copay or coinsurance is then based on their specific plan benefits. Those with Medicare or Medicaid may have different coverage and cost-sharing arrangements. Patient assistance programs offered by the manufacturer, GlaxoSmithKline (GSK), can also help reduce out-of-pocket expenses for eligible individuals [1].

How does insurance coverage impact Anoro Ellipta pricing?

Insurance coverage is a primary driver of the final cost for Anoro Ellipta. Plans differ in their tier placement of medications, with lower tiers generally having lower copays. Some insurance plans may require prior authorization before covering Anoro Ellipta, meaning a healthcare provider must get approval from the insurer. Patients are advised to check with their insurance provider to understand their specific coverage details and potential costs.

Are there Anoro Ellipta coupons or discount cards available?

Yes, savings cards and coupons are often available for Anoro Ellipta. GSK offers a savings program that can reduce copayments for commercially insured patients. These offers are typically found on the drug's official website or through pharmacy discount card providers. The availability and terms of these discounts can change.

When does Anoro Ellipta's patent expire?

Anoro Ellipta, a combination inhaler containing umeclidinium and vilanterol, is protected by patents. Patent expiry dates are critical for understanding when generic versions might become available, which could lead to lower prices. Information on Anoro Ellipta's patent status and projected expiry dates can be found through resources like DrugPatentWatch.com [2]. For example, as of late 2023, some of the key patents for Anoro Ellipta were listed with expiry dates around 2034, though patent litigation and exclusivities can affect the actual market entry of generics.

How does Anoro Ellipta compare to other COPD inhalers?

Anoro Ellipta is used for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). It is a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA) combination. Other COPD inhalers may contain different combinations of bronchodilators, such as other LAMA/LABA combinations (e.g., Stiolto Respimat), inhaled corticosteroids (ICS) and LABA combinations (e.g., Advair Diskus, Symbicort), or triple therapy combinations including an ICS, LABA, and LAMA (e.g., Trelegy Ellipta). The choice of inhaler often depends on the severity of COPD, individual patient response, and physician recommendation.

---

Sources:

[1] GlaxoSmithKline. Anoro Ellipta Savings Card. https://www.anoro.com/savings-and-support
[2] DrugPatentWatch. Anoro Ellipta Patent Expiry. https://drugpatentwatch.com/p/anoro-ellipta-umeclidinium-vilanterol